Related Experiment Video
Updated: May 31, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Comparing Outcomes of the Hepatitis C Virus Cascade of Care Between a Peer-Led Program and Drug Treatment Services in
Rajani Raghu1, Stuart Smith2, Freddy Green1
1UK Health Security Agency, London, UK.
Objectives:
The United Kingdom has committed to World Health Organization goals to eliminate hepatitis C virus (HCV) by 2030. Peer-led services (PLS) may enhance health care engagement and treatment outcomes. We compared progression through the HCV care cascade between those tested in a community using PLS (PLS group) with a population tested in drug services (non-PLS group) in England.
Methods:
We extracted data on individuals with HCV-RNA test results from a laboratory surveillance system (2019-2023) and linked them to a national HCV treatment database. We identified individuals tested by the Hepatitis C Trust as having received PLS. We compared differences along the care cascade using the Pearson χ2 test.
Results:
A total of 14 094 individuals in the PLS group (72.9% male; median age, 43 y) and 46 568 individuals in the non-PLS group (70.6% male; median age, 44 y) received a positive HCV-RNA test result. Significantly more individuals from the PLS group than the non-PLS group were linked to treatment (83% vs 51%) and initiated treatment (73% vs 33%; both P < .001). Among those with a treatment outcome, 75% in the PLS group versus 80% in the non-PLS group achieved a sustained virologic response (SVR) (P < .001). Significantly more individuals achieved SVR among those receiving a positive HCV-RNA test result in the PLS group than in the non-PLS group (36% vs 11%; P < .001).
Conclusion:
A key strength in peer-led models lies in linkage to treatment when compared with drug services alone. This finding highlights the importance of ongoing support for peer-led programs helping medically underserved populations living with HCV progress to treatment and achieve elimination.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles